Six Indian firms ink pact with UN to supply HIV drugs and other top pharma news

India Infoline News Service | Mumbai | July 08, 2016 10:20 IST

Drug firm Zydus Cadila has inked a generic manufacturing pact with the Medicines Patent Pool for manufacturing global pharma major Bristol-Myers Squibb’s daclatasvir tablets used in the treatment of Hepatitis C.

Doctor prescription and medicine
Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among seven drug makers which have signed licensing pact with UNbacked Medicines Patent Pool (MPP) for producing HIV and Hepatitis C drugs. A total of nine new sub-licensing agreements to produce generic versions of key World Health Organisation-priority HIV and Hepatitis C treatments have been signed by MPP with these pharmaceuticals firms and Shanghai-based Desano. (DNA)

Drug firm Zydus Cadila has inked a generic manufacturing pact with the Medicines Patent Pool for manufacturing global pharma major Bristol-Myers Squibb’s daclatasvir tablets used in the treatment of Hepatitis C. The company “has signed a non-exclusive, royalty-free agreement with the Medicines Patent Pool (MPP) for the generic production of Bristol-Myers Squibb’s daclatasvir, a novel direct-acting antiviral that is proven to help cure multiple genotypes of the Hepatitis C Virus,” Zydus Cadila said in a statement. The agreement sub licenses Zydus to produce and sell daclatasvir in 112 low and middle-income countries, it added. (Hindu)

Kal Sundaram, chief executive at Taro Pharmaceutical Industries Ltd, the Israeli subsidiary of Sun Pharmaceutical Industries Ltd, will step down by the end of this calendar year, the company said. Sundaram will return to India to take up an executive position at Sun Pharma after completing his assignment at Taro at the end of 2016, a company statement said on Wednesday. (Mint)

hares of Lupin Ltd gained 6.25% in a flat market after India's third largest drug maker said the US Food and Drug Administration (USFDA) has closed the inspection of its Goa facility and issued an establishment inspection report. The company said it has received a notification in this respect. The USFDA, which inspected Lupin’s Goa plant in July, 2015, had made nine Form 483 observations related to inadequacies and adherence to standard operating procedures. There was another plant inspection in March, and nine more Form 483 observations. (Mint)

BSE 1,036.70 [15.80] ([1.50]%)

***Note: This is a NSE Chart

 

Advertisements

  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.